There is no shortage of anti-tuberculosis drugs in the country and there has been a regular supply of anti-TB drugs to all the states and UTs from the central level under the National TB Elimination Programme (NTEP), said an official release.
According to the release from the Ministry of Health and Family Welfare, "There is no shortage of anti-tuberculosis drugs in the country. There has been a regular supply of anti-TB drugs to all the states and UTs from the central level under the NTEP throughout the year."
"Regular assessments are conducted to evaluate the stock positions at various levels, from central warehouses to peripheral health institutes," it said.
Further, states and UTs have been provisioned with resources for local procurement in limited quantities as and when required to meet the emergent requirements.
The details of the stock positions of anti-tuberculosis drugs are as under: The year-wise details for demand and disbursement of tuberculosis drugs from 2019 to 2023, as per Indent and Release Orders, are placed at https://tbcindia.gov.in/showfile.php?lid=3721
Earlier this year, the Ministry of Health and Family Welfare issued a statement refuting recent media reports that suggest a shortage of anti-tuberculosis (TB) drugs in India and question the efficacy of these drugs under the NTEP.
The ministry had labelled these reports as vague and ill-informed, lacking specific information about the availability of anti-TB medicines in stock.
The Ministry of Health and Family Welfare assures that significant efforts are in place to ensure the availability of these crucial anti-TB drugs, with regular assessments conducted to evaluate stock positions at various levels, from central warehouses to peripheral health institutes.
Therefore, the media reports were deemed vague and ill-informed, not accurately reflecting the actual stock of anti-TB drugs in the country.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)